Bristol-Myers Squibb Company (BMYS)

Overview

Bristol-Myers Squibb Company is an eminent global biopharmaceutical firm engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative biopharmaceutical products. With a spectrum of treatments covering hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases, the company has established a significant footprint in the healthcare sector. Initially founded as Bristol-Myers Company in 1887, it has evolved over the decades to become a leader in the biopharmaceutical industry, headquartered in Princeton, New Jersey. The company's operational reach spans globally, selling products through a diversified channel mix including wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Products and Services

• Eliquis: Used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Opdivo: A versatile anti-cancer medication approved for a wide range of cancers including bladder, blood, colorectal, head and neck, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), lung, melanoma, mesothelioma, stomach, and esophageal cancer.
• Pomalyst/Imnovid: Designed for the treatment of multiple myeloma, providing vital options for patients with this challenging form of cancer.
• Orencia: Offers relief for individuals suffering from active rheumatoid arthritis and psoriatic arthritis, aiming to improve quality of life and reduce symptoms.
• Sprycel: Specifically targeted at treating Philadelphia chromosome-positive chronic myeloid leukemia, a particular type of leukemia characterized by the presence of an abnormal chromosome.
• Yervoy: This medication is used for the treatment of patients with unresectable or metastatic melanoma, offering a beam of hope for those battling this form of skin cancer.
• Empliciti: Another option in the fight against multiple myeloma, providing an additional avenue for treatment for patients.
• Abecma: Crafted for the treatment of relapsed or refractory multiple myeloma, Abecma offers a new horizon for patients who have not responded to previous treatments.
• Reblozyl: A therapeutic option for the treatment of anemia, focusing on a condition that can severely impact the overall health and well-being of patients.
• Opdualag: Specifically indicated for the treatment of unresectable or metastatic melanoma, enhancing the arsenal against this aggressive skin cancer.
• Zeposia: Approved to treat relapsing forms of multiple sclerosis, this medication aims to reduce the frequency of relapses and slow the disease's progression.
• Breyanzi: Used for the treatment of relapsed or refractory large B-cell lymphoma, Breyanzi provides a valuable tool in the fight against this type of cancer.
• Onureg: A treatment option for acute myelogenous leukemia (AML), offering new hope for patients with this aggressive form of leukemia.
• Inrebic: Targets myelofibrosis, a serious bone marrow disorder, by offering patients a chance for improved outcomes and symptom relief.
• Camzyos: Focuses on the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), aimed at enhancing functional capacity and reducing symptoms in affected patients.
• Sotyktu: Provides relief for patients suffering from moderate-to-severe plaque psoriasis, offering a new approach in managing this chronic skin condition.
• Augtyro: Specifically developed for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), marking a significant step forward in targeted cancer therapy.
• Revlimid: An oral immunomodulatory drug critical for the treatment of multiple myeloma, playing a key role in managing this form of cancer.
• Abraxane: Used to treat breast cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer, Abraxane extends therapeutic options for patients facing these serious diseases.